Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activat...
Main Authors: | Sandra Bacián Martínez, Carlos Navarro Cuéllar, Carlos Navarro Vila, Edurne Palacios Weiss, Roser Pujol Romanyá, Álvaro del Amo Fernández de Velasco, Margarita Escrig de Teijeiro, José Luis del Castillo Pardo de Vera, Irene Rodríguez Pérez, Arturo Sánchez-Pérez, José J. Zamorano-León, Antonio López-Farré, María Isabel García-Hidalgo Alonso, Ignacio Navarro Cuéllar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/11/16/7646 |
Similar Items
-
DENOSUMAB-RELATED OSTEONECROSIS OF THE JAWS: A CASE REPORT
by: Milena Petkova, et al.
Published: (2017-03-01) -
Denosumab Related Osteonecrosis of Jaw: a Case Report
by: Marco Vinícius de Sales Lima, et al.
Published: (2018-12-01) -
A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
by: Satoe Okuma, et al.
Published: (2020-05-01) -
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
by: Vittorio Fusco, et al.
Published: (2018-09-01) -
Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series
by: Guillermo Pardo-Zamora, et al.
Published: (2021-01-01)